Articles related to GLP-1 RECEPTOR AGONISTS

The American College of Physicians issued a living clinical guideline recommending semaglutide and tirzepatide as first-line pharmacologic treatments with lifestyle modifications for nonpregnant adults with obesity (BMI 30 kg/m2 or higher) or overweight (BMI 27 to 30 kg/m2) with at least one weight-related comorbidity, with phentermine-topiramate, liraglutide, and naltrexone-bupropion designated as second-, third-, and fourth-line options respectively based on GRADE evidence review.

GLP-1 receptor agonist use was associated with a 41% lower overall risk of obesity-related cancers in a retrospective cohort of more than 229,000 non-diabetic patients with obesity, with the largest risk reductions observed in endometrial, pancreatic, colorectal, and multiple myeloma.

Post-hoc analyses of the ATTAIN-1 and ATTAIN-2 trials found that oral orforglipron at maximum dose produced significant weight reductions across all menopausal stages in women with obesity, with and without type 2 diabetes, at 72 weeks.

The GINA 2026 update introduces age-stratified primary care flowcharts for asthma exacerbation management, expands biologic guidance including depemokimab, and adds a formal red-flag list for fatal or near-fatal asthma risk in adults and adolescents.

Four major societies jointly published the first multidisciplinary guideline for cardiovascular-kidney-metabolic syndrome, introducing a standardized staging system and unified treatment framework across cardiology, nephrology, endocrinology, and primary care.

A retrospective analysis of more than 840,000 patients with breast cancer found lower all-cause mortality and reduced recurrence risk among those with obesity or type 2 diabetes who received GLP-1 receptor agonists compared with similar patients who did not, though the study did not establish causation.